ATC code L01

ATC code L01 Antineoplastic agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3] Subgroup L01 is part of the anatomical group L Antineoplastic and immunomodulating agents.[4] Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL01.[5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
ATC code LAntineoplastic agentsEndocrineImmunostimulantsImmunosuppressantsAnatomical Therapeutic Chemical Classification SystemWorld Health OrganizationL Antineoplastic and immunomodulating agentsveterinaryATCvet codesCyclophosphamideChlorambucilMelphalanChlormethineIfosfamideTrofosfamidePrednimustineBendamustineMelphalan flufenamideBusulfanTreosulfanMannosulfanThiotepaTriaziquoneCarboquoneCarmustineLomustineSemustineStreptozocinFotemustineNimustineRanimustineUramustineEtoglucidMitobronitolPipobromanTemozolomideDacarbazineMethotrexateRaltitrexedPemetrexedPralatrexateMercaptopurineTioguanineCladribineFludarabineClofarabineNelarabineRabacfosadineCytarabineFluorouracilTegafurCarmofurGemcitabineCapecitabineAzacitidineDecitabineFloxuridineTrifluridineVinblastineVincristineVindesineVinorelbineVinflunineVintafolideEtoposideTeniposideDemecolcinePaclitaxelDocetaxelCabazitaxelTopotecanIrinotecanEtirinotecan pegolBelotecanTrabectedinDactinomycinDoxorubicinDaunorubicinEpirubicinAclarubicinZorubicinIdarubicinMitoxantronePirarubicinValrubicinAmrubicinPixantroneBleomycinPlicamycinMitomycinIxabepiloneUtideloneImatinibDasatinibNilotinibBosutinibPonatinibAsciminibGefitinibErlotinibAfatinibOsimertinibRociletinibOlmutinibDacomitinibIcotinibLazertinibMobocertinibAumolertinibVemurafenibDabrafenibEncorafenibCrizotinibCeritinibAlectinibBrigatinibLorlatinibTrametinibCobimetinibBinimetinibSelumetinibPalbociclibRibociclibAbemaciclibTemsirolimusEverolimusRidaforolimusSirolimusLapatinibNeratinibTucatinibRuxolitinibFedratinibPacritinibMomelotinibAxitinibCediranibTivozanibFruquintinibIbrutinibAcalabrutinibZanubrutinibOrelabrutinibPirtobrutinibTirabrutinibIdelalisibCopanlisibAlpelisibDuvelisibParsaclisibErdafitinibPemigatinibInfigratinibFutibatinibSunitinibSorafenibPazopanibVandetanibRegorafenibMasitinibCabozantinibLenvatinibNintedanibMidostaurinQuizartinibLarotrectinibGilteritinibEntrectinibPexidartinibCapmatinibAvapritinibRipretinibTepotinibSelpercatinibPralsetinibSurufatinibUmbralisibSitravatinibCapivasertibRepotrectinibToceranibRituximabOfatumumabObinutuzumabInotuzumab ozogamicinMoxetumomab pasudotoxDaratumumabIsatuximabTrastuzumabPertuzumabTrastuzumab emtansineTrastuzumab deruxtecanMargetuximabZanidatamabCetuximabPanitumumabNecitumumabNivolumabPembrolizumabDurvalumabAvelumabAtezolizumabCemiplimabDostarlimabTislelizumabRetifanlimabSugemalimabSerplulimabToripalimabBevacizumabRamucirumabEdrecolomabGemtuzumab ozogamicinCatumaxomabIpilimumabBrentuximab vedotinDinutuximab betaBlinatumomabElotuzumabMogamulizumabOlaratumabBermekimabTafasitamabEnfortumab vedotinPolatuzumab vedotinBelantamab mafodotinOportuzumab monatoxSacituzumab govitecanAmivantamabTremelimumabNaxitamabLoncastuximab tesirineTisotumab vedotinTeclistamabMosunetuzumabMirvetuximab soravtansineEpcoritamabGlofitamabTalquetamabZolbetuximabElranatamabTarlatamabOdronextamabDatopotamab deruxtecanPatritumab deruxtecanPertuzumab and trastuzumabNivolumab and relatlimabCisplatinCarboplatinOxaliplatinSatraplatinProcarbazinePorfimer sodiumMethyl aminolevulinateAminolevulinic acidTemoporfinEfaproxiralPadeliporfinTretinoinAlitretinoinBexaroteneBortezomibCarfilzomibIxazomibVorinostatRomidepsinPanobinostatBelinostatEntinostatTucidinostatResminostatVismodegibSonidegibGlasdegibOlaparibNiraparibRucaparibTalazoparibVeliparibPamiparibabirateroneTalimogene laherparepvecAxicabtagene ciloleucelTisagenlecleucelCiltacabtagene autoleucelBrexucabtagene autoleucelIdecabtagene vicleucelLisocabtagene maraleucelTabelecleucelNadofaragene firadenovecLifileucelObecabtagene autoleucelEnasidenibIvosidenibOlutasidenibVorasidenibAmsacrineAsparaginaseAltretamineHydroxycarbamideLonidaminePentostatinMasoprocolEstramustineMitoguazoneTiazofurineMitotanePegaspargaseArsenic trioxideDenileukin diftitoxCelecoxibAnagrelideOblimersenOmacetaxine mepesuccinateEribulinAfliberceptVenetoclaxVosaroxinPlitidepsinEpacadostatSelinexorTagraxofuspLurbinectedinTazemetostatSotorasibBelzutifanTebentafuspAdagrasibNavitoclaxEflornithineImetelstatNirogacestatDarinaparsinPelabresibCalaspargase pegolTigilanol tiglateCytarabine and daunorubicinNational Institutes of Healthchemotherapeutic agentsM phasemicrotubuleVinca alkaloidsTaxanesLarotaxelOrtataxelTesetaxelEpothilonesDNA replicationantimetabolitesS phaseFolic acidDihydrofolate reductase inhibitorAminopterinThymidylate synthase inhibitorPurineAdenosine deaminase inhibitorHalogenatedribonucleotide reductase inhibitorsThiopurinePyrimidineDoxifluridine+gimeracil/oteracilDNA polymerase inhibitor+daunorubicinRibonucleotide reductase inhibitorHypomethylating agentDeoxyribonucleotideTopoisomerase inhibitorsCamptothecaCamptothecinExatecanLurtotecanRubitecanPodophyllumIntercalationAnthracyclines+cytarabineAnthracenedionesLosoxantroneBisantreneCrisnatolMenogarilCrosslinking of DNAAlkylatingNitrogen mustardsNitrosoureasAlkyl sulfonatesAziridinesTriethylenemelaminePlatinum-basedDicycloplatinNedaplatinHydrazinesTriazenesMitozolomideStreptomycesMitomycinsPhotosensitizersPorphyrin derivativesTalaporfinVerteporfinEnzyme inhibitorsTipifarnibinhibitorsAlvocidibSeliciclibOprozomibTiazofurinPARP inhibitorFuzuloparib+abiraterone acetateInavolisibReceptor antagonistsAtrasentanRetinoid X receptorSex steroidTestolactoneAsparagine depletersElesclomolElsamitrucinLucanthoneRetinoidsWHO-EMWithdrawnClinical trialsTargeted cancer therapymonoclonal antibodiesReceptor tyrosine kinaseHER1/EGFRHER2/neu+hyaluronidaseVEGF-ALeukemialymphomalymphoidIbritumomabTositumomabBrentuximabAlemtuzumabmyeloidAxatilimabCosibelimab+relatlimabZenocutuzumabTyrosine kinase inhibitorsTovorafenibRTK class IIILestaurtinibSemaxanibEnsartinibNon-receptorbcr-ablRadotinibJanus kinaseBaricitinibFilgotinibBruton'sfusion proteinproapoptoticprohibitinAdipotideexotoxinmTOR inhibitorshedgehogCDK inhibitorsDalpiciclibTrilaciclibPi3K inhibitorsRevumenibFibroblast growth factor receptorTunlametinib